致癌基因成瘾与放射肿瘤学:光子和碳离子放疗在ALK-EML4易位非小细胞肺癌中的效果
本研究探讨了ALK抑制剂TAE684联合光子或碳离子放疗对ALK阳性与野生型非小细胞肺癌细胞的影响。结果显示TAE684对EML4-ALK易位的H3122细胞增殖抑制的IC50约为8.2 nM,而A549和LLC细胞在100 nM下未达到IC50;TAE684联合放疗在H3122细胞中表现出协同效应,碳离子放疗的敏化增强比约为1.61(p < 0.05)。结论提示ALK抑制联合放疗可能对该亚群NSCLC治疗有益,需进一步评估。
要点
- TAE684抑制H3122细胞增殖的IC50约为8.2 nM。
- A549和LLC细胞对TAE684相对耐药,100 nM下未达IC50。
- TAE684联合碳离子放疗在H3122中敏化增强比约1.61(p < 0.05)。
核心结论
- 首次报道TAE684联合放疗在EML4-ALK阳性肺癌细胞中具有协同效应。
- 除光子放疗外,ALK抑制也增强碳离子粒子放疗的效果。
- 数据提示ALK抑制联合放疗对该亚群NSCLC治疗有益,需进一步评估。
研究设计与样本
- 研究使用人非小细胞肺癌细胞系A549(野生型ALK)、H3122(EML4-ALK易位)和小鼠Lewis肺癌(LLC)细胞。
- 细胞接受1-4 Gy X射线(320 keV)和碳离子(扩展布拉格峰,245.4-257.0 MeV/u)照射。
- TAE684给药浓度范围为0-100 nM。
- 通过克隆存活、增殖和caspase 3/7表达水平评估凋亡,使用延时活细胞显微镜。
主要发现
- TAE684以剂量依赖方式抑制H3122细胞增殖,IC50约为8.2 nM。
- A549和LLC细胞对TAE684相对耐药,增殖实验中浓度达100 nM时未达到IC50。
- TAE684的抗增殖效应在H3122细胞中被放疗增强。
- TAE684显著敏化H3122细胞对碳离子粒子治疗,敏化增强比约为1.61(p < 0.05)。
- 联合治疗后H3122细胞中caspase 3/7活性明显增强。
临床怎么用
- 对于EML4-ALK阳性NSCLC细胞,ALK抑制剂TAE684联合光子或碳离子放疗可增强细胞杀伤效应。
- 该联合策略可能适用于ALK阳性NSCLC亚群,但需进一步临床评估。
局限性
- 研究仅使用细胞系模型,未涉及动物实验或临床试验。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with Echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) positive lung cancer are sensitive to ALK-kinase inhibitors. TAE684 is a potent second generation ALK inhibitor that overcomes Crizotinib resistance. Radiotherapy is an integral therapeutic component of locally advanced lung cancer. Therefore, we sought to investigate the effects of combined radiotherapy and ALK-inhibition via TAE684 in ALK-positive vs. wild type lung cancer cells. METHODS: Human non-small cell lung cancer (NSCLC) cell lines harboring wild-type ALK (A549), EML4-ALK translocation (H3122) and murine Lewis Lung Cancer (LLC) cells were investigated. Cells were irradiated with 1-4 Gy X-Rays (320 keV) and carbon ions (Spread-out Bragg Peak, SOBP (245.4-257.0 MeV/u)) at Heidelberg Ion Therapy center. TAE684 was administered at the dose range 0-100 nM. Clonogenic survival, proliferation and apoptosis via caspase 3/7 expression level were assessed in all three cell lines using time-lapse live microscopy. RESULTS: TAE684 inhibited the proliferation of H3122 cells in a dose-dependent manner with a half maximal inhibitory concentration (IC50) of ~ 8.2 nM. However, A549 and LLC cells were relatively resistant to TAE684 and IC50 was not reached at concentrations tested (up to 100 nM) in proliferation assay. The antiproliferative effect of TAE684 was augmented by radiotherapy in H3122 cells. TAE684 significantly sensitized H3122 cells to particle therapy with carbon ions (sensitizer enhancement ratio ~1.61, p < 0.05). Caspase 3/7 activity was evidently enhanced after combination therapy in H3122 cells. CONCLUSIONS: This is the first report demonstrating synergistic effects of combined TAE684 and radiotherapy in EML4-ALK positive lung cancer cells. In addition to conventional photon radiotherapy, ALK-inhibition also enhanced the effects of particle irradiation using carbon ions. Our data indicate beneficial effects of combined ALK-inhibition and radiotherapy in treatment of this distinct subpopulation of NSCLC that warrant further evaluation.
引用
- Dai Y, Wei Q, Schwager C, et al. Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC. Radiat Oncol. 2018. PMID: 29304828. doi:10.1186/s13014-017-0947-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。